Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Wednesday that it has been granted European patent EP4172199B1 for exidavnemab by the European Patent Office.
Entering into force on 14 May 2025, the new patent offers protection until 2041 with a potential extension to 2046.
Exidavnemab is a monoclonal antibody in development for the treatment of synucleinopathies, including Parkinson's disease and Multiple System Atrophy. The drug targets and removes aggregated alpha-synuclein, which contributes to neuronal damage, with the aim of preserving nerve cell function and slowing disease progression.
This patent expands BioArctic's intellectual property portfolio in Europe and supports its strategy to develop disease-modifying treatments for neurodegenerative conditions.
CEO Gunilla Osswald emphasised the significance of the patent as a reflection of BioArctic's innovation in addressing brain diseases.
Akeso doses first patient in Phase III Ivonescimab small cell lung cancer trial
Polymer Factory-led study advances nanocarrier-based drug delivery for aggressive cancers
RemeGen receives FDA approval to advance RC148 into Phase II trials for solid tumours
Spinogenix reports positive first cohort results from Phase 2a trial in Alzheimer's disease
Sebela Pharmaceuticals completes tegoprazan Phase 3 TRIUMpH programme in GERD with positive results
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
Jazz Pharmaceuticals' Modeyso approved by US FDA for H3 K27M-mutant diffuse midline glioma treatment
Sanyou Bio wins 'Best Customer Satisfaction CRO Award'
Kowa begins Phase 3 safety trial of Nicox's NCX 470 in Japan, triggering EUR2m milestone
MetaVia collaborates with Syntekabio to explore AI-driven indications for DA-1241
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist